These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26513046)

  • 1. Phenol 8% solution for the treatment of epidermal growth factor receptor inhibitor-induced periungual pyogenic granulomas.
    Panariello L; Caro G; Bianca D; Fabbrocini G
    G Ital Dermatol Venereol; 2015 Dec; 150(6):755-6. PubMed ID: 26513046
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of pyogenic granulomas following gefitinib therapy with partial matricectomy and phenolization.
    Dika E; Balestri R; Vaccari S; Alessandro Fanti P; Misciali C; Patrizi A
    J Dermatolog Treat; 2009; 20(6):374-5. PubMed ID: 19954397
    [No Abstract]   [Full Text] [Related]  

  • 3. Tracheal granuloma pyogenicum with erlotinib treatment for lung cancer.
    Putora PM; Benz G; Rodriguez R; Brutsche M; Früh M
    Eur Respir J; 2011 Nov; 38(5):1228-30. PubMed ID: 22045792
    [No Abstract]   [Full Text] [Related]  

  • 4. Paclitaxel-associated subungual pyogenic granuloma: report in a patient with breast cancer receiving paclitaxel and review of drug-induced pyogenic granulomas adjacent to and beneath the nail.
    Paul LJ; Cohen PR
    J Drugs Dermatol; 2012 Feb; 11(2):262-8. PubMed ID: 22270214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Erlotinib-induced acneiform rash not affecting previously irradiated skin].
    Eguren C; Domínguez-Fernández I; Santiago-Sánchez-Mateos DI; García-Díez A
    Actas Dermosifiliogr; 2010 Mar; 101(2):186-7. PubMed ID: 20223168
    [No Abstract]   [Full Text] [Related]  

  • 6. Gefitinib: a cause of pyogenic granulomalike lesions of the nail.
    High WA
    Arch Dermatol; 2006 Jul; 142(7):939. PubMed ID: 16847224
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug-related nail disease.
    Piraccini BM; Alessandrini A
    Clin Dermatol; 2013; 31(5):618-26. PubMed ID: 24079591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lapatinib.
    Dhillon S; Wagstaff AJ
    Drugs; 2007; 67(14):2101-8; discussion 2109-10. PubMed ID: 17883289
    [No Abstract]   [Full Text] [Related]  

  • 9. Disseminated herpes simplex virus infection following epidermal growth factor tyrosine kinase inhibitor therapy for non-small-cell lung carcinoma.
    Teh BW; Worth LJ
    Intern Med J; 2012 Nov; 42(11):1269-70. PubMed ID: 23157525
    [No Abstract]   [Full Text] [Related]  

  • 10. Pyogenic granuloma caused by afatinib: Case report and review of the literature.
    Inoue A; Sawada Y; Nishio D; Nakamura M
    Australas J Dermatol; 2017 Feb; 58(1):61-62. PubMed ID: 26603180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Periungual pyogenic granuloma following imatinib therapy in a patient with chronic myelogenous leukemia.
    Dika E; Barisani A; Vaccari S; Fanti PA; Ismaili A; Patrizi A
    J Drugs Dermatol; 2013 May; 12(5):512-3. PubMed ID: 23652942
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and long-term efficacy of partial matricectomy and phenolization for the treatment of pyogenic granuloma-like lesions induced by epidermal growth factor receptor inhibitors.
    Mariano M; Lorenzi S; De Padova MP; Fabbrocini G; Cameli N
    G Ital Dermatol Venereol; 2020 Aug; 155(4):517-518. PubMed ID: 30249089
    [No Abstract]   [Full Text] [Related]  

  • 13. Topical phenol as a conservative treatment for periungual pyogenic granuloma.
    Losa Iglesias ME; Becerro de Bengoa Vallejo R
    Dermatol Surg; 2010 May; 36(5):675-8. PubMed ID: 20384744
    [No Abstract]   [Full Text] [Related]  

  • 14. Partial excision of matrix and phenolic ablation for the treatment of ingrowing toenail: a 36-month follow-up of 197 treated patients.
    Vaccari S; Dika E; Balestri R; Rech G; Piraccini BM; Fanti PA
    Dermatol Surg; 2010 Aug; 36(8):1288-93. PubMed ID: 20573175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of epidermal growth factor receptor inhibitor-induced severe paronychia with pyogenic granuloma-like lesions with topical betaxolol: an open-label observation study.
    Yen CF; Hsu CK; Yang HS; Lee CN; Chi CC; Chung WH; Wang CL; Pang JS; Wang CW; Ko YS; Lu CW
    Int J Dermatol; 2020 Mar; 59(3):326-332. PubMed ID: 31763692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva).
    Lübbe J; Masouyé I; Dietrich PY
    Dermatology; 2008; 216(3):247-9. PubMed ID: 18182820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib and maintenance therapy of non-small cell lung cancer. Inadequate assessment; authorisation unjustified.
    Prescrire Int; 2011 Oct; 20(120):234. PubMed ID: 21970082
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor.
    Dainichi T; Tanaka M; Tsuruta N; Furue M; Noda K
    Dermatology; 2003; 207(3):324-5. PubMed ID: 14571080
    [No Abstract]   [Full Text] [Related]  

  • 19. Gutter method: noninvasive management of ingrown nails caused by epidermal growth factor inhibitor treatment.
    Harada K; Yamaguchi M; Miyajima S; Kawamura T; Shibagaki S; Shimada S
    Clin Exp Dermatol; 2012 Aug; 37(6):703-4. PubMed ID: 22548530
    [No Abstract]   [Full Text] [Related]  

  • 20. Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
    Bragg J; Pomeranz MK
    Dermatol Online J; 2007 Jan; 13(1):1. PubMed ID: 17511934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.